Equity · Healthcare
ONC
NASDAQBeOne Medicines (ONC)
The line runs 359 USD on 10 August through 362 USD on 5 October, on a scale from 340 to 380. Days the market did not trade hold the previous close, flat.
- Market cap
- 537.5B USD
- P/E (TTM)
- 593.4
- Revenue, year to Dec 2025
- 5.3B USD
- EPS, diluted, year to Dec 2025
- 0.19 USD
- 52-week range
- 260 USD – 377 USD
- Avg volume
- 27.3K
as of Oct 5, 2026
Have BeOne Medicines (ONC) insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, BeOne Medicines insiders reported 11 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 15 Jul 2026, show no open-market purchase.
Form 4, 90 days to 9 Nov 2026, newest reported trade 27 Oct 2026
Buys 0Sells 11Net sold $134.85MOther filings 6
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 27 Oct 2026 | Wang XiaodongDirector | Sell | 31,028 | 11.3M USD |
| 13 Oct 2026 | Wang XiaodongDirector | Sell | 31,027 | 10.9M USD |
| 30 Sep 2026 | Lee Chan HenrySVP, General Counsel | Sell | 1,115 | 418K USD |
| 28 Sep 2026 | Wang XiaodongDirector | Sell | 31,028 | 11.3M USD |
| 08 Sep 2026 | Wang XiaodongDirector | Sell | 38,287 | 13.4M USD |
| 01 Sep 2026 | Ball Titus B.Principal Accounting Officer | Sell | 132 | 47K USD |
| 25 Aug 2026 | Wu XiaobinPresident and COO | Sell | 280 | 106K USD |
| 12 Aug 2026 | OYLER JOHNChief Executive Officer | Sell | 54,892 | 19.7M USD |
| 11 Aug 2026 | OYLER JOHNChief Executive Officer | Sell | 70,907 | 25.7M USD |
| 11 Aug 2026 | Lee Chan HenrySVP, General Counsel | Sell | 2,666 | 960K USD |
| 10 Aug 2026 | OYLER JOHNChief Executive Officer | Sell | 115,011 | 41.2M USD |
| Sold | 11 open-market sales | 376,373 | $134.85M |
6 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 27 Oct 2026 | Wang XiaodongDirector | Option exercise | 31,028 | 1.1M USD |
| 13 Oct 2026 | Wang XiaodongDirector | Option exercise | 31,027 | 1.1M USD |
| 28 Sep 2026 | Wang XiaodongDirector | Option exercise | 31,028 | 1.1M USD |
| 14 Sep 2026 | BAKER BROS. ADVISORS LPDirector | Option exercise | 61,536 | 2.3M USD |
| 08 Sep 2026 | Wang XiaodongDirector | Option exercise | 31,027 | 1.1M USD |
| 11 Aug 2026 | Lee Chan HenrySVP, General Counsel | Option exercise | 2,666 | 510K USD |
Which funds hold BeOne Medicines (ONC)?
1 of the 45 institutional funds we track reported a BeOne Medicines position for the quarter ended 30 Sep 2026 — a combined 367K USD; the latest of those filings landed 06 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Fisher Asset Management | New position | 1,002 | 367K USD |
What has been filed or recorded for BeOne Medicines (ONC)?
The filings we hold for BeOne Medicines, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Sep 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS 0.25 USD | |
| 30 Sep 2026 | Financials | Total assets | 9.9B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 5.8B USD | at period end |
| 29 Sep 2026 | Fails to deliver | Shares failed to deliver | 27,633 shares | 10.1M USD notional · 0.002% of shares out |
| 24 Sep 2026 | Fails to deliver | Shares failed to deliver | 23 shares | 8K USD notional · <0.001% of shares out |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS 0.16 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 0.15 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 0.19 USD | |
| 31 Dec 2025 | Financials | Revenue | 5.3B USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 286.9M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 0.19 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 0.08 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS 0.06 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS 0.00 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −0.47 USD |
BeOne Medicines (ONC): frequently asked questions
What did BeOne Medicines shares close at?
BeOne Medicines closed at 362.00 USD on 5 Oct 2026, up 1.12% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is BeOne Medicines’ market cap?
BeOne Medicines is worth 537.5B USD by market value as of 5 Oct 2026, which is the share price times the shares on issue from its SEC filings.
What is BeOne Medicines’ P/E ratio?
BeOne Medicines has a price-to-earnings ratio of 593.4, as of 5 Oct 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is BeOne Medicines’ revenue?
BeOne Medicines reported revenue of 5.3B USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have BeOne Medicines insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, BeOne Medicines insiders reported 11 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 15 Jul 2026, show no open-market purchase. A further 6 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own BeOne Medicines?
1 of the 45 funds we track reported a BeOne Medicines position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Fisher Asset Management. See Funds
When did BeOne Medicines last report earnings?
BeOne Medicines last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 0.25 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings